Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (7): 659-664.DOI: 10.3969/j.issn.1673-8640.2023.07.008
Previous Articles Next Articles
Received:
2022-05-24
Revised:
2022-12-30
Online:
2023-07-30
Published:
2023-09-18
CLC Number:
MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease[J]. Laboratory Medicine, 2023, 38(7): 659-664.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.07.008
组别 | 例数 | TG/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | sd-LDL-C/(mmol/L) | TC/(mmol/L) |
---|---|---|---|---|---|---|
CHD组 | 200 | 1.73±0.76* | 2.45±0.51* | 1.13±0.26* | 1.16±0.21 | 4.73±1.26* |
男性 | 78 | 1.72±0.75# | 2.39±0.49# | 1.14±0.25# | 1.15±0.19 | 4.66±1.11# |
女性 | 122 | 1.73±0.76△ | 2.48±0.51△ | 1.13±0.26△ | 1.17±0.22 | 4.80±1.24△ |
对照组 | 200 | 1.65±0.67 | 2.14±0.42 | 1.25±0.32 | 1.12±0.17 | 3.32±1.17 |
男性 | 79 | 1.65±0.66 | 2.11±0.40 | 1.27±0.29 | 1.12±0.16 | 3.20±1.18 |
女性 | 121 | 1.66±0.67 | 2.16±0.41 | 1.24±0.33 | 1.12±0.18 | 3.35±1.11 |
组别 | apo A/(g/L) | apo B/(g/L) | apo E/(mg/L) | Lp(a)/(mg/L) | Lp-PLA2/(pg/mL) | |
CHD组 | 1.31±0.35* | 0.98±0.26* | 54.44±17.49* | 29.86±5.37* | 235.62±69.35* | |
男性 | 1.32±0.36# | 1.01±0.24# | 53.25±17.11# | 30.05±5.01# | 211.09±58.29# | |
女性 | 1.30±0.33△ | 0.97±0.27△ | 55.01±17.84△ | 29.11±5.43△ | 241.22±71.33△ | |
对照组 | 1.59±0.37 | 0.83±0.21 | 32.55±6.49 | 21.42±6.53 | 153.22±43.15 | |
男性 | 1.59±0.35 | 0.83±0.19 | 30.56±5.62 | 21.77±6.11 | 149.50±38.55 | |
女性 | 1.58±0.38 | 0.82±0.22 | 32.88±6.66 | 21.31±6.42 | 155.90±43.59 |
组别 | 例数 | TG/(mmol/L) | LDL-C/(mmol/L) | HDL-C/(mmol/L) | sd-LDL-C/(mmol/L) | TC/(mmol/L) |
---|---|---|---|---|---|---|
CHD组 | 200 | 1.73±0.76* | 2.45±0.51* | 1.13±0.26* | 1.16±0.21 | 4.73±1.26* |
男性 | 78 | 1.72±0.75# | 2.39±0.49# | 1.14±0.25# | 1.15±0.19 | 4.66±1.11# |
女性 | 122 | 1.73±0.76△ | 2.48±0.51△ | 1.13±0.26△ | 1.17±0.22 | 4.80±1.24△ |
对照组 | 200 | 1.65±0.67 | 2.14±0.42 | 1.25±0.32 | 1.12±0.17 | 3.32±1.17 |
男性 | 79 | 1.65±0.66 | 2.11±0.40 | 1.27±0.29 | 1.12±0.16 | 3.20±1.18 |
女性 | 121 | 1.66±0.67 | 2.16±0.41 | 1.24±0.33 | 1.12±0.18 | 3.35±1.11 |
组别 | apo A/(g/L) | apo B/(g/L) | apo E/(mg/L) | Lp(a)/(mg/L) | Lp-PLA2/(pg/mL) | |
CHD组 | 1.31±0.35* | 0.98±0.26* | 54.44±17.49* | 29.86±5.37* | 235.62±69.35* | |
男性 | 1.32±0.36# | 1.01±0.24# | 53.25±17.11# | 30.05±5.01# | 211.09±58.29# | |
女性 | 1.30±0.33△ | 0.97±0.27△ | 55.01±17.84△ | 29.11±5.43△ | 241.22±71.33△ | |
对照组 | 1.59±0.37 | 0.83±0.21 | 32.55±6.49 | 21.42±6.53 | 153.22±43.15 | |
男性 | 1.59±0.35 | 0.83±0.19 | 30.56±5.62 | 21.77±6.11 | 149.50±38.55 | |
女性 | 1.58±0.38 | 0.82±0.22 | 32.88±6.66 | 21.31±6.42 | 155.90±43.59 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
CHD组 | 200 | 49.35±3.78* | 37.85±2.16* | 57.52±6.81* |
男性 | 78 | 48.66±2.87# | 37.44±2.22# | 58.22±7.01# |
女性 | 122 | 49.75±3.82△ | 38.02±2.26△ | 57.31±6.70△ |
对照组 | 200 | 45.19±3.53 | 30.25±2.27 | 65.51±2.95 |
男性 | 79 | 44.65±3.51 | 29.88±2.21 | 64.41±3.11 |
女性 | 121 | 45.76±3.67 | 30.51±2.30 | 65.77±2.78 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
CHD组 | 200 | 49.35±3.78* | 37.85±2.16* | 57.52±6.81* |
男性 | 78 | 48.66±2.87# | 37.44±2.22# | 58.22±7.01# |
女性 | 122 | 49.75±3.82△ | 38.02±2.26△ | 57.31±6.70△ |
对照组 | 200 | 45.19±3.53 | 30.25±2.27 | 65.51±2.95 |
男性 | 79 | 44.65±3.51 | 29.88±2.21 | 64.41±3.11 |
女性 | 121 | 45.76±3.67 | 30.51±2.30 | 65.77±2.78 |
指标 | EDV | ESV | LVEF | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
TG | 0.582 | <0.001 | 0.524 | <0.001 | -0.625 | <0.001 | ||
LDL-C | 0.626 | <0.001 | 0.593 | <0.001 | -0.573 | <0.001 | ||
HDL-C | -0.566 | <0.001 | -0.621 | <0.001 | 0.546 | <0.001 | ||
TC | 0.771 | <0.001 | 0.726 | <0.001 | -0.635 | <0.001 | ||
apo A | -0.623 | <0.001 | -0.526 | <0.001 | 0.658 | <0.001 | ||
apo B | 0.632 | <0.001 | 0.711 | <0.001 | -0.578 | <0.001 | ||
apo E | 0.593 | <0.001 | 0.726 | <0.001 | -0.633 | <0.001 | ||
Lp(a) | 0.668 | <0.001 | 0.692 | <0.001 | -0.627 | <0.001 | ||
Lp-PLA2 | 0.591 | <0.001 | 0.623 | <0.001 | -0.663 | <0.001 |
指标 | EDV | ESV | LVEF | |||||
---|---|---|---|---|---|---|---|---|
r值 | P值 | r值 | P值 | r值 | P值 | |||
TG | 0.582 | <0.001 | 0.524 | <0.001 | -0.625 | <0.001 | ||
LDL-C | 0.626 | <0.001 | 0.593 | <0.001 | -0.573 | <0.001 | ||
HDL-C | -0.566 | <0.001 | -0.621 | <0.001 | 0.546 | <0.001 | ||
TC | 0.771 | <0.001 | 0.726 | <0.001 | -0.635 | <0.001 | ||
apo A | -0.623 | <0.001 | -0.526 | <0.001 | 0.658 | <0.001 | ||
apo B | 0.632 | <0.001 | 0.711 | <0.001 | -0.578 | <0.001 | ||
apo E | 0.593 | <0.001 | 0.726 | <0.001 | -0.633 | <0.001 | ||
Lp(a) | 0.668 | <0.001 | 0.692 | <0.001 | -0.627 | <0.001 | ||
Lp-PLA2 | 0.591 | <0.001 | 0.623 | <0.001 | -0.663 | <0.001 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
LDL-C≤3.40 mmol/L组 | 146 | 47.35±3.70 | 36.85±1.90 | 59.02±6.61 |
LDL-C >3.40 mmol/L组 | 54 | 52.50±3.55 | 39.10±2.15 | 54.43±5.90 |
t值 | 15.230 | 13.500 | 18.300 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
LDL-C≤3.40 mmol/L组 | 146 | 47.35±3.70 | 36.85±1.90 | 59.02±6.61 |
LDL-C >3.40 mmol/L组 | 54 | 52.50±3.55 | 39.10±2.15 | 54.43±5.90 |
t值 | 15.230 | 13.500 | 18.300 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
TC≤5.17 mmol/L组 | 110 | 46.70±3.45 | 36.48±2.01 | 60.02±6.50 |
TC>5.17 mmol/L组 | 90 | 63.05±3.55 | 39.96±2.10 | 54.04±5.80 |
t值 | 18.200 | 16.280 | 20.050 | |
P值 | <0.001 | <0.001 | <0.001 |
组别 | 例数 | EDV/mm | ESV/mm | LVEF/% |
---|---|---|---|---|
TC≤5.17 mmol/L组 | 110 | 46.70±3.45 | 36.48±2.01 | 60.02±6.50 |
TC>5.17 mmol/L组 | 90 | 63.05±3.55 | 39.96±2.10 | 54.04±5.80 |
t值 | 18.200 | 16.280 | 20.050 | |
P值 | <0.001 | <0.001 | <0.001 |
项目 | EDV | ||||
---|---|---|---|---|---|
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.255 | 0.012 | 13.10 | <0.001 | 2.150(1.010~3.225) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.271 | 0.105 | 8.650 | <0.001 | 2.289(1.280~3.405) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.101 | 0.007 | 4.30 | <0.001 | 2.020(1.009~3.880) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.088 | 0.075 | 3.040 | <0.001 | 1.985(1.030~3.875) |
项目 | ESV | ||||
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.127 | 0.091 | 6.345 | <0.001 | 1.850(1.025~2.660) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.118 | 0.170 | 8.95 | <0.001 | 2.119(1.015~3.815) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.077 | 0.067 | 4.785 | <0.001 | 1.746(1.005~2.800) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.108 | 0.110 | 3.08 | <0.001 | 1.973(1.009~4.010) |
项目 | LVEF | ||||
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.669 | 0.025 | 8.60 | <0.001 | 1.980(1.220~3.005) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.725 | 0.041 | 4.300 | <0.001 | 1.681(1.105~2.335) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.300 | 0.045 | 4.555 | <0.001 | 1.666(1.122~2.144) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.305 | 0.040 | 5.035 | <0.001 | 1.585(1.110~2.146) |
项目 | EDV | ||||
---|---|---|---|---|---|
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.255 | 0.012 | 13.10 | <0.001 | 2.150(1.010~3.225) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.271 | 0.105 | 8.650 | <0.001 | 2.289(1.280~3.405) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.101 | 0.007 | 4.30 | <0.001 | 2.020(1.009~3.880) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.088 | 0.075 | 3.040 | <0.001 | 1.985(1.030~3.875) |
项目 | ESV | ||||
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.127 | 0.091 | 6.345 | <0.001 | 1.850(1.025~2.660) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.118 | 0.170 | 8.95 | <0.001 | 2.119(1.015~3.815) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | 0.077 | 0.067 | 4.785 | <0.001 | 1.746(1.005~2.800) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | 0.108 | 0.110 | 3.08 | <0.001 | 1.973(1.009~4.010) |
项目 | LVEF | ||||
β值 | 标准误 | Wald值 | P值 | OR值(95%CI) | |
单因素分析 | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.669 | 0.025 | 8.60 | <0.001 | 1.980(1.220~3.005) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.725 | 0.041 | 4.300 | <0.001 | 1.681(1.105~2.335) |
多因素分析① | |||||
LDL-C(≤3.40 mmol/L与>3.40 mmol/L) | -0.300 | 0.045 | 4.555 | <0.001 | 1.666(1.122~2.144) |
TC(≤5.17 mmol/L与>5.17 mmol/L) | -0.305 | 0.040 | 5.035 | <0.001 | 1.585(1.110~2.146) |
[1] |
GBD 2016 Causes of Death Collaborators. Global,regional,and national age-sex specific mortality for 264 causes of death,1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017, 390(10100):1151-1210.
DOI URL |
[2] | 《中国心血管病报告2017》概要[J]. 中国循环杂志, 2018, 33(1):1-8. |
[3] | 黄曼萍, 梁东辉, 刘永源, 等. 高密度脂蛋白在不同证型冠心病患者血清中的表达及意义[J]. 广东医学, 2015, 36(21):3395-3398. |
[4] |
MARBER M. The future of myocardial injury biomarkers in cardiovascular disease:looking beyond cardiac troponins[J]. Cardiovasc Res, 2018, 114(6):e39-e40.
DOI URL |
[5] | 王志剑, 邓之敏, 李雪华, 等. 人血浆脂蛋白相关磷脂酶A2与冠心病合并糖尿病及高血压的相关性研究[J]. 临床检验杂志(电子版), 2018, 7(2):203-205. |
[6] |
FIHN S D, BLANKENSHIP J C, ALEXANDER K P, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,and the American Association for Thoracic Surgery,Preventive Cardiovascular Nurses Association,Society for Cardiovascular Angiography and Interventions,and Society of Thoracic Surgeons[J]. J Am Coll Cardiol,2014, 64(18):1929-1949.
DOI URL |
[7] | 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10):937-950. |
[8] | 杨林, 葛百平, 姜珊, 等. TG/HDL-C比值与冠心病患者致病风险的关系及诊断价值[J]. 中国医药导报, 2021, 18(11):66-69. |
[9] | 王黎, 韩泉, 谢丹. 血清胱抑素C、同型半胱氨酸、甘油三酯/高密度脂蛋白胆固醇比值联合检测对老年冠心病的诊断价值[J]. 临床和实验医学杂志, 2021, 20(9):931-934. |
[10] | 段厚全, 王鹤. LDL-C、LP-a与Hcy联合检测在冠心病诊治中的应用[J]. 海南医学, 2015,(10):1463-1465. |
[11] | 胡晓蔚, 孙建琦, 章锡林, 等. 载脂蛋白A-1及高密度脂蛋白在冠心病中作用的比较[J]. 皖南医学院学报, 2019, 38(1):60-63. |
[12] | LI J, CHEN L L, WANG J G, et al. Association between apolipoprotein E gene and heart blood stasis syndrome in premature coronary heart disease pedigrees within the hunan han nation population[J]. Biomed Res, 2017, 28(21):9543-9548. |
[13] | 张爱爱, 韩伟, 宋建英, 等. 血浆脂蛋白相关磷脂酶A2浓度与不同类型冠心病相关性研究[J]. 心肺血管病杂志, 2020, 39(2):139-142. |
[14] | 李春晖. 福辛普利联合美托洛尔治疗冠心病心力衰竭的临床效果观察[J]. 河南医学研究, 2016, 25(2):302. |
[15] | 周依蒙, 郑鹏翔, 陈德, 等. 冠心病合并心力衰竭患者血清Cat S、Periostin、NT-proBNP水平与心功能指标、炎症因子的关系研究[J]. 国际检验医学杂志, 2021, 42(3):270-273. |
[1] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[2] | JIN Suli, ZHAO Jing, ZHANG Jie, HOU Xuening, FANG Yanchao, YANG Li, MI Yujing. Relationship between thyroid hormones and bile acid subfractions and blood lipids in Graves' disease patients [J]. Laboratory Medicine, 2023, 38(6): 563-568. |
[3] | WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589. |
[4] | ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA1c,NT-proBNP,Hcy,SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286. |
[5] | SU Zhenzhen, ZOU Jihua, WANG Huimin, XU Weifeng, DING Fang, ZHANG Jingmei, WANG Zhanke. Consistency of serum LDL-P and LDL-C determination results [J]. Laboratory Medicine, 2023, 38(2): 148-152. |
[6] | XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945. |
[7] | ZHANG Yifan, LI Changping, ZHANG Lili, CHEN Zhong. Relationship between plasma galectin 3 and low-density lipoprotein cholesterol stratified by ages in patients with cardiovascular disease [J]. Laboratory Medicine, 2023, 38(1): 8-13. |
[8] | SHEN Jianguo, LI Tingting, SONG Yunxiao, BIAN Xiaobo, ZHANG Linlin, JIN Xiaoling. Clinical role of blood lipid in brittle fracture elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(6): 535-538. |
[9] | SHEN Ying, XU Xiaoping, ZHANG Lele, DU Yongping, MENG Chao. Clinical value of LDL-C determination in non-fasting blood samples [J]. Laboratory Medicine, 2022, 37(11): 1049-1056. |
[10] | PENG Yanjun, HAN Xuejing, TANG Hongxia, CHEN Junmeng, JIA Kegang. Correlation between nuclear magnetic resonance spectroscopy and traditional biochemical determination methods analyzer for determining blood lipid [J]. Laboratory Medicine, 2021, 36(7): 733-737. |
[11] | LIU Jinyan, ZHAO Juntao, XIANG Mingjie. Mechanism and application of serum amyloid A in clinical diseases [J]. Laboratory Medicine, 2021, 36(7): 756-760. |
[12] | DAI Yanpeng, YUAN Enwu, LIU Junjie, LI Yushan, WANG Quanxian. Analysis of the appropriate levels of blood lipid among healthy pregnant women in Zhengzhou [J]. Laboratory Medicine, 2021, 36(6): 604-608. |
[13] | LI Jing, QUAN Hui, ZENG Zhirong, WEI Yi. Establishment of the reference interval of small and dense low-density lipoprotein cholesterol in apparently healthy adults in Chengdu [J]. Laboratory Medicine, 2021, 36(6): 609-614. |
[14] | WANG Linlin, FAN Jun, YE Chenyu, YING Chunmei. Correlation between blood lipid and carotid atherosclerotic plaque in elderly patients with coronary heart disease [J]. Laboratory Medicine, 2021, 36(6): 618-622. |
[15] | KONG Fanbin, YUAN Yong, JI Yong, LI Zheng, CHEN Qi, WU Xiaoming, GAO Hui. Correlation between serum retinol binding protein 4,homocysteine and blood lipid with atherosclerosis [J]. Laboratory Medicine, 2021, 36(5): 467-470. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||